Mark Lazenby, PhD, associate professor at Yale School of Nursing and incoming president of American Psychosocial Oncology Society (APOS), discusses the Screening for Psychosocial Distress Program, which was launched in 2014 by APOS in partnership with Yale School of Nursing.
Mark Lazenby, PhD, associate professor at Yale School of Nursing and incoming president of American Psychosocial Oncology Society (APOS), discusses the Screening for Psychosocial Distress Program, which was launched in 2014 by APOS in partnership with Yale School of Nursing.
Two cancer care professionals, ideally from different disciplines, are trained over two years to implement comprehensive distress screening, evaluate that screening, refer the patient to additional resources if needed and properly document the results.
The participants attend two APOS conferences and learn how to implement live in workshops. Interested cancer care professionals can apply online at http://www.apos-society.org.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive
Cranbury, NJ 08512